StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)

Close on Nov 17, 2026Market cap $73.93MP/E –Yield –

Coherus Oncology operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Coherus Oncology's operating cash flow for the twelve months ending Jun 30, 2026 was -$186.03M. For fiscal 2025 it was -$138.51M. The highest annual figure on record is $154.15M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$138.51M–
FY2024Dec 31, 2024-$20.44M–
FY2023Dec 31, 2023-$174.88M–
FY2022Dec 31, 2022-$241.12M–
FY2021Dec 31, 2021-$37.43M-124.3%
FY2020Dec 31, 2020$154.15M+443.6%
FY2019Dec 31, 2019$28.36M–
FY2018Dec 31, 2018-$159.27M–
FY2017Dec 31, 2017-$200.29M–
FY2016Dec 31, 2016-$252.55M–
FY2015Dec 31, 2015-$107.99M–
FY2014Dec 31, 2014-$23.93M-255.1%
FY2013Dec 31, 2013$15.42M–
FY2012Dec 31, 2012-$18.25M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$62.09M–
Q1 FY2026Mar 31, 2026-$57.89M–
Q4 FY2025Dec 31, 2025-$19.72M-168.9%
Q3 FY2025Sep 30, 2025-$46.34M–
Q2 FY2025Jun 30, 2025-$46.63M-178.1%
Q1 FY2025Mar 31, 2025-$25.83M–
Q4 FY2024Dec 31, 2024$28.61M–
Q3 FY2024Sep 30, 2024-$62.02M–
Q2 FY2024Jun 30, 2024$59.73M–
Q1 FY2024Mar 31, 2024-$46.77M–
Q4 FY2023Dec 31, 2023-$12.94M–
Q3 FY2023Sep 30, 2023-$54.30M–
Q2 FY2023Jun 30, 2023-$38.92M–
Q1 FY2023Mar 31, 2023-$68.73M–
Q4 FY2022Dec 31, 2022-$99.95M–
Q3 FY2022Sep 30, 2022-$37.09M-370.5%
Q2 FY2022Jun 30, 2022-$50.04M–
Q1 FY2022Mar 31, 2022-$54.05M-4053.5%
Q4 FY2021Dec 31, 2021-$52.32M-258.0%
Q3 FY2021Sep 30, 2021$13.71M-71.0%
Q2 FY2021Jun 30, 2021-$188.00K-100.3%
Q1 FY2021Mar 31, 2021$1.37M-89.9%
Q4 FY2020Dec 31, 2020$33.12M+87.0%
Q3 FY2020Sep 30, 2020$47.35M-13.8%
Q2 FY2020Jun 30, 2020$60.19M+374.8%
Q1 FY2020Mar 31, 2020$13.48M–
Q4 FY2019Dec 31, 2019$17.71M–
Q3 FY2019Sep 30, 2019$54.95M–
Q2 FY2019Jun 30, 2019$12.68M–
Q1 FY2019Mar 31, 2019-$56.98M–
Q4 FY2018Dec 31, 2018-$47.36M–
Q3 FY2018Sep 30, 2018-$42.79M–
Q2 FY2018Jun 30, 2018-$35.53M–
Q1 FY2018Mar 31, 2018-$33.58M–
Q4 FY2017Dec 31, 2017-$29.92M–
Q3 FY2017Sep 30, 2017-$41.51M–
Q2 FY2017Jun 30, 2017-$55.57M–
Q1 FY2017Mar 31, 2017-$73.28M–
Q4 FY2016Dec 31, 2016-$86.89M–
Q3 FY2016Sep 30, 2016-$61.95M–

More Coherus Oncology figures

See a number that looks wrong?